In 30% of these, mutations were found at a low allele frequency in pre-treatment tumor tissue [107], suggesting that newly detected RAS mutation in plasma from patients refractory to anti-EGFR treatment may derive from rare, pre-existing clones in primary tumors. This evidence concerns the gene EGFR and neoplasm.